"Rapid Novor Inc...announced today that its diagnostic laboratory has received a provisional license from the Ontario Ministry of Health (MOH) for its EasyM® assay, enabling the company to begin testing patients in Canada. This milestone represents the first time highly sensitive measurable residual disease (MRD) monitoring is available to multiple myeloma patients within Canada, marking a transformative advancement in the standard of care."